{"pub_date": "2016-07-08T00:10:59+0000", "subsection_name": null, "lead_paragraph": "The study was testing the use of genetically engineered cells as a treatment for cancer, which had shown promising earlier results.", "print_page": "6", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "POLLACK", "firstname": "Andrew", "role": "reported"}], "original": "By ANDREW POLLACK"}, "multimedia": [], "section_name": "Business Day", "headline": {"print_headline": "Juno Halts Cancer Treatment Trial Using Gene-Altered Cells After 3 Deaths", "main": "Juno Halts Cancer Trial Using Gene-Altered Cells After 3 Deaths"}, "source": "The New York Times", "blog": [], "word_count": "526", "web_url": "http://www.nytimes.com/2016/07/08/business/juno-halts-cancer-trial-using-gene-altered-cells-after-3-deaths.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "The study was testing the use of genetically engineered cells as a treatment for cancer, which had shown promising earlier results....", "_id": "577eef9538f0d8658862afff", "abstract": "Food and Drug Admin halts Juno Therapeutics clinical trial following deaths of three patients from brain swelling; complications from side effects slow promising cancer therapy that involved genetically engineered cells; Juno shares fall 27 percent on news. ", "keywords": [{"rank": "1", "name": "organizations", "value": "Juno Therapeutics Inc", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Cancer", "is_major": "Y"}, {"rank": "3", "name": "subject", "value": "Genetic Engineering", "is_major": "Y"}, {"rank": "5", "name": "subject", "value": "Clinical Trials", "is_major": "N"}, {"rank": "6", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N"}, {"rank": "7", "name": "organizations", "value": "Food and Drug Administration", "is_major": "Y"}, {"rank": "8", "name": "subject", "value": "Tests (Medical)", "is_major": "Y"}]}